Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment

ABSTRACT: Visceral leishmaniasis (VL) affects over 500 000 people worldwide each year. The disease occurs in the Mediterranean basin, Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly along the Caribbean coast and the...

Descripción completa

Detalles Bibliográficos
Autores: Vélez Bernal, Iván Darío, Colmenares Roldan, Lina María, Aguirre Muñoz, Carlos Arturo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:Colombia
Institución:Universidad de Antioquia
Repositorio:Repositorio UdeA
Idioma:inglés
OAI Identifier:oai:bibliotecadigital.udea.edu.co:10495/32321
Acceso en línea:https://hdl.handle.net/10495/32321
Access Level:acceso abierto
Palabra clave:Leishmaniasis Visceral
Leishmaniasis, Visceral
Pentavalent antimonial
Therapeutic failure
Liposomal Amphotericin B
id CO_cb732a1dfd12e4e3ae43a298377b2b06
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/32321
network_acronym_str CO
network_name_str Colombia
repository_id_str
spelling Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatmentVélez Bernal, Iván DaríoColmenares Roldan, Lina MaríaAguirre Muñoz, Carlos ArturoLeishmaniasis VisceralLeishmaniasis, VisceralPentavalent antimonialTherapeutic failureLiposomal Amphotericin BABSTRACT: Visceral leishmaniasis (VL) affects over 500 000 people worldwide each year. The disease occurs in the Mediterranean basin, Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly along the Caribbean coast and the Magdalena River Valley and 90% of VL cases occur in children under the age of five. The first line of treatment is chemotherapy with pentavalent antimonial compounds, including sodium stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®). These compounds are the ones most used in Colombia, at a dose of 20 mg/kg/day for 28 days. Nevertheless resistance of L. infantum to pentavalent antimonials is becoming an important problem. No cases of VL resistant to pentavalent antimonial compounds have previously been reported from Colombia. This report describes the two cases of VL resistance to antimonial compounds in a girl and a boy who did not respond to previous treatment with Pentacarinat® and Glucantime® regimens but were treated successfully with liposomal amphotericin B. Based on our findings, we recommend liposomal amphotericin B as the first line of treatment for VL due to its low toxicity, shorter administration period and the low price obtained by WHO.COL0015099Universidade de São Paulo, Instituto de Medicina Tropical de São PauloPrograma de Estudio y Control de Enfermedades Tropicales (PECET)São Paulo, Brasil2022-11-25T12:35:24Z2022-11-25T12:35:24Z2009info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTCASOReporte de caso6application/pdfapplication/pdf0036-4665https://hdl.handle.net/10495/3232110.1590/S0036-466520090004000111678-9946engRev. Inst. Med. Trop. São Paulo.info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc/4.0/reponame:Repositorio UdeAinstname:Universidad de Antioquiainstacron:Universidad de Antioquia2022-11-25T12:35:25Z
dc.title.none.fl_str_mv Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
title Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
spellingShingle Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
Vélez Bernal, Iván Darío
Leishmaniasis Visceral
Leishmaniasis, Visceral
Pentavalent antimonial
Therapeutic failure
Liposomal Amphotericin B
title_short Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
title_full Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
title_fullStr Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
title_full_unstemmed Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
title_sort Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment
dc.creator.none.fl_str_mv Vélez Bernal, Iván Darío
Colmenares Roldan, Lina María
Aguirre Muñoz, Carlos Arturo
author Vélez Bernal, Iván Darío
author_facet Vélez Bernal, Iván Darío
Colmenares Roldan, Lina María
Aguirre Muñoz, Carlos Arturo
author_role author
author2 Colmenares Roldan, Lina María
Aguirre Muñoz, Carlos Arturo
author2_role author
author
dc.subject.none.fl_str_mv Leishmaniasis Visceral
Leishmaniasis, Visceral
Pentavalent antimonial
Therapeutic failure
Liposomal Amphotericin B
topic Leishmaniasis Visceral
Leishmaniasis, Visceral
Pentavalent antimonial
Therapeutic failure
Liposomal Amphotericin B
description ABSTRACT: Visceral leishmaniasis (VL) affects over 500 000 people worldwide each year. The disease occurs in the Mediterranean basin, Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly along the Caribbean coast and the Magdalena River Valley and 90% of VL cases occur in children under the age of five. The first line of treatment is chemotherapy with pentavalent antimonial compounds, including sodium stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®). These compounds are the ones most used in Colombia, at a dose of 20 mg/kg/day for 28 days. Nevertheless resistance of L. infantum to pentavalent antimonials is becoming an important problem. No cases of VL resistant to pentavalent antimonial compounds have previously been reported from Colombia. This report describes the two cases of VL resistance to antimonial compounds in a girl and a boy who did not respond to previous treatment with Pentacarinat® and Glucantime® regimens but were treated successfully with liposomal amphotericin B. Based on our findings, we recommend liposomal amphotericin B as the first line of treatment for VL due to its low toxicity, shorter administration period and the low price obtained by WHO.
publishDate 2009
dc.date.none.fl_str_mv 2009
2022-11-25T12:35:24Z
2022-11-25T12:35:24Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_2df8fbb1
https://purl.org/redcol/resource_type/ARTCASO
Reporte de caso
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 0036-4665
https://hdl.handle.net/10495/32321
10.1590/S0036-46652009000400011
1678-9946
identifier_str_mv 0036-4665
10.1590/S0036-46652009000400011
1678-9946
url https://hdl.handle.net/10495/32321
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Rev. Inst. Med. Trop. São Paulo.
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.format.none.fl_str_mv 6
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo
Programa de Estudio y Control de Enfermedades Tropicales (PECET)
São Paulo, Brasil
publisher.none.fl_str_mv Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo
Programa de Estudio y Control de Enfermedades Tropicales (PECET)
São Paulo, Brasil
dc.source.none.fl_str_mv reponame:Repositorio UdeA
instname:Universidad de Antioquia
instacron:Universidad de Antioquia
instname_str Universidad de Antioquia
instacron_str Universidad de Antioquia
institution Universidad de Antioquia
reponame_str Repositorio UdeA
collection Repositorio UdeA
_version_ 1825050850937012224
score 15.811543

Similares en LA Referencia